Amgen today announced that the European Commission (EC) has granted marketing authorization for IMDYLLTRA® (tarlatamab) as a monotherapy to treat adults with extensive-stage small cell lung cancer (ES ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results